Improvements in Health-Related Quality of Life in Patients with Severe Sickle Cell Disease After Exagamglogene Autotemcel
Authors
Discussion
Loading...
Member takes
Implication
Phase 3 trial shows exagamglogene autotemcel improves health-related quality of life and reduces pain in patients with sickle cell disease.
Key Points
- Exagamglogene autotemcel improved health-related quality of life in both adults and adolescents with severe sickle cell disease.
- 97% of participants in the Phase 3 trial experienced elimination of vaso-occlusive crises, significantly enhancing their quality of life.
- Observational analysis revealed substantial improvements in pain scores and various patient-reported outcomes by Month 6 and sustained through Month 36.
- These findings highlight the promise of gene-edited therapies in transforming the management of sickle cell disease, indicating potential wide-scale applicability.
Cite This Study
Sharma et al. (2025) studied this question.